Sign In
Buy BNTX
$89.59
+1.14 (+1.29%)
At Close: Jun 04, 2026
Moderna, BioNTech on the rise amid concerns over new variant, China outbreak
03:10pm, Monday, 14'th Mar 2022 Seeking Alpha
Many vaccine makers are surging in Monday trading amid concerns over a new COVID-19 variant, deltacron, and as China experiences its worst outbreak since early 2020.
Here's Why BioNTech Shares Are Rising On Monday
03:09pm, Monday, 14'th Mar 2022
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 14.8% at $155.65. Strength is possibly due to a spike in COVID-19 cases in China, which could lift vaccine sector sentiment.
Pfizer-BioNTech''s COVID-19 Shot Moderately Effective Against Omicron In Kids Aged 5 to 15, CDC Study Shows
01:37pm, Monday, 14'th Mar 2022 Benzinga
The Pfizer Inc (NYSE: PFE ) - BioNTech SE (NASDAQ: BNTX ) vaccine is only moderately effective against the omicron variant when tested in children ages 5 to 15. According to a study conducted by the Centers for Disease Control and Prevention (CDC) and Abt Associates, the shot showed 59% efficacy in those ages 12 to 15 and 31% in those ages 5 to 11. The study also found that vaccinated children spent less time sick in … Full story available on Benzinga.com
Thinking about trading options or stock in Merck, Linde, BioNTech, Bank of America, or Apple?
01:31pm, Monday, 14'th Mar 2022 Benzinga
NEW YORK , March 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRK, LIN, BNTX, BAC, and AAPL. … Full story available on Benzinga.com
Why BioNTech, Dynavax, Novavax, and Pfizer Stocks Are Jumping Today
12:24pm, Monday, 14'th Mar 2022
The broader stock market bounce and news from China are fueling gains for all four vaccine stocks.
Moderna and BioNTech Stocks Rally on Booster Chatter and a China Covid Surge
12:23pm, Monday, 14'th Mar 2022
Shares of Covid-19 vaccine makers jump on news of climbing Covid-19 cases in China and growing talk of a fourth booster round in the U.S.
Is It Too Late to Buy BioNTech Stock?
04:45pm, Saturday, 12'th Mar 2022 The Motley Fool
The market has probably priced in the impacts of its biggest source of revenue.
Is It Too Late to Buy BioNTech Stock?
11:45am, Saturday, 12'th Mar 2022
The market has probably priced in the impacts of its biggest source of revenue.
COVID vaccine less effective against Omicron in younger kids, study shows
11:11pm, Friday, 11'th Mar 2022 Kwhen Finance
Covid was declared a pandemic two years ago and now we''re finally moving on — but public health experts say it''s not over
10:48am, Friday, 11'th Mar 2022 Kwhen Finance
CDC finds COVID-19 vaccination rate in young children relatively low
06:33pm, Thursday, 10'th Mar 2022 Seeking Alpha
Even though Pfizer (PFE)/BioNTech (BNTX) COVID-19 vaccine is authorized for use in children 5-11 years old, a relatively low percentage of them have received a shot.
Moderna and Other Vaccine Stocks Finally Rallied Wednesday. Buyers May Be Back.
03:02pm, Thursday, 10'th Mar 2022 Barron''s
After months of poor performance, Moderna, BioNTech, and Novavax surged Wednesday. Bears now "are less negative" on Moderna, says one analyst.
Vaccine Stocks BioNTech, Moderna Pop On Fourth Dose — But IBD/TIPP Poll Says Few People Care
05:06pm, Wednesday, 09'th Mar 2022 Investor''s Business Daily
Vaccine stocks popped Wednesday, but remain broadly under pressure. Their Covid wares are predicted to fall as the virus becomes endemic.
BioNTech (BNTX), Regeneron Expand Agreement for Lung Cancer Study
12:47pm, Wednesday, 09'th Mar 2022
BioNTech (BNTX) expands its strategic collaboration deal with Regeneron to evaluate the combo of BNT116 plus Libtayo for treating advanced non-small cell lung cancer.
BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC
04:43pm, Tuesday, 08'th Mar 2022 Benzinga
BioNTech SE (NASDAQ: BNTX ) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in advanced non-small-cell lung cancer (NSCLC). Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate the combination in different patient populations with … Full story available on Benzinga.com
